Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBH589 (Panobinostat) Dose-Escalation in Advanced Hematological Malignancies
NCT00621244Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2003
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of panobinostat in hematologic malignancy, acute myeloid leukemia (AML), Hodgkin lymphoma (HL) and 4 more (4 arms), sponsored by Novartis. Primary endpoint: Dose Limiting Toxicity. Started Mar 2003; status: completed.
02
Drugs
panobinostat
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)Hodgkin lymphoma (HL)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00621244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621244.